Alnylam Pharmaceuticals (ALNY) Expected to Announce Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is expected to be releasing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Alnylam Pharmaceuticals to post earnings of $1.43 per share and revenue of $1.1574 billion for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Alnylam Pharmaceuticals Stock Up 0.0%

ALNY opened at $351.96 on Thursday. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $495.55. The firm has a 50 day moving average price of $394.28 and a 200 day moving average price of $424.94. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The company has a market cap of $46.50 billion, a PE ratio of 1,466.50 and a beta of 0.35.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ALNY. HC Wainwright decreased their price objective on shares of Alnylam Pharmaceuticals from $570.00 to $510.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Oppenheimer assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price target for the company. Royal Bank Of Canada lowered their price target on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a report on Tuesday, January 20th. Piper Sandler restated an “overweight” rating and set a $489.00 price objective (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Finally, Leerink Partners decreased their target price on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Twenty-two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $477.13.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,510 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $547,933.70. Following the sale, the executive vice president directly owned 22,511 shares in the company, valued at $8,168,566.57. The trade was a 6.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Tolga Tanguler sold 1,510 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the transaction, the executive vice president directly owned 29,728 shares in the company, valued at approximately $10,787,399.36. The trade was a 4.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 56,955 shares of company stock valued at $24,072,733 in the last three months. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. CIBC Bancorp USA Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $2,132,000. Captrust Financial Advisors increased its holdings in Alnylam Pharmaceuticals by 118.7% in the third quarter. Captrust Financial Advisors now owns 7,669 shares of the biopharmaceutical company’s stock valued at $3,497,000 after buying an additional 4,163 shares during the last quarter. Coldstream Capital Management Inc. raised its stake in Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 38 shares in the last quarter. Danske Bank A S acquired a new stake in Alnylam Pharmaceuticals during the third quarter valued at approximately $26,178,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.